Agios Pharmaceuticals principal accounting officer sells shares for $78,134

CAMBRIDGE, MA—Theodore James Jr. Washburn, the Principal Accounting Officer at Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), recently sold 2,272 shares of common stock. The shares were sold at a price of $34.39 each, totaling $78,134. This transaction took place on February 5, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The sale occurred near the stock’s current trading price of $34.38, with analysts setting price targets ranging from $46 to $75.

The sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units, as outlined in Washburn’s restricted stock unit agreement from February 1, 2023. Following this transaction, Washburn holds 5,437 shares directly.

Earlier, on February 1, 2025, Washburn acquired 6,896 shares of common stock through the vesting of restricted stock units, which were originally granted on February 1, 2023, and vested in full on the same date in 2025. These restricted stock units were converted at no cost to Washburn.

Agios Pharmaceuticals, headquartered in Cambridge, Massachusetts, focuses on developing innovative therapies for genetically defined diseases. The company has demonstrated solid performance with a 43% stock return over the past year and maintains a healthy current ratio of 8.99, indicating strong liquidity. Get deeper insights and access to 7 additional ProTips with InvestingPro.

In other recent news, Agios Pharmaceuticals has been at the forefront of several key developments. The U.S. Food and Drug Administration (FDA) recently accepted Agios’s supplemental New Drug Application (sNDA) for PYRUKYND® (mitapivat), a potential treatment for adults with thalassemia, a rare blood disorder. The FDA also approved an update to the prescribing information for PYRUKYND, which includes new details on liver injury risks observed in patients treated with the drug.

In addition, the European Commission has granted orphan medicinal product designation to mitapivat for the treatment of sickle cell disease, following a similar designation by the FDA. This designation is reserved for innovative treatments for conditions affecting fewer than 5 in 10,000 people and includes incentives such as reduced regulatory fees and a decade of market exclusivity post-approval.

RBC Capital has also updated its outlook on Agios, maintaining an Outperform rating and increasing the price target to $57 from $55. This adjustment follows Agios’s recent presentations, which highlighted promising clinical data. These are among the recent developments for Agios Pharmaceuticals.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.